Literature DB >> 11857078

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.

Dharminder Chauhan1, Daniel Auclair, Elisabeth K Robinson, Teru Hideshima, Guilan Li, Klaus Podar, Deepak Gupta, Paul Richardson, Robert L Schlossman, Nancy Krett, Lan Bo Chen, Nikhil C Munshi, Kenneth C Anderson.   

Abstract

Our previous studies have characterized Dexamethasone (Dex)-induced apoptotic signaling pathways in multiple myeloma (MM) cells; however, related transcriptional events are not fully defined. In the present study, gene expression profiles of Dex-treated MM cells were determined using oligonucleotide arrays. Dex triggers early transient induction of many genes involved in cell defense/repair-machinery. This is followed by induction of genes known to mediate cell death and repression of growth/survival-related genes. The molecular and genetic alterations associated with Dex resistance in MM cells are also unknown. We compared the gene expression profiles of Dex-sensitive and Dex-resistant MM cells and identified a number of genes which may confer Dex-resistance. Finally, gene profiling of freshly isolated MM patient cells validates our in vitro MM cell line data, confirming an in vivo relevance of these studies. Collectively, these findings provide insights into the basic mechanisms of Dex activity against MM, as well as mechanisms of Dex-resistance in MM cells. These studies may therefore allow improved therapeutic uses of Dex, based upon targeting genes that regulate MM cell growth and survival.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11857078     DOI: 10.1038/sj.onc.1205205

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

Review 1.  The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.

Authors:  Sarah K Johnson; Christoph J Heuck; Anthony P Albino; Pingping Qu; Qing Zhang; Bart Barlogie; John D Shaughnessy
Journal:  Int J Hematol       Date:  2011-10-15       Impact factor: 2.490

2.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

Review 3.  Novel therapeutic targets in myeloma bone disease.

Authors:  S L Webb; C M Edwards
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

Review 4.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

5.  A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A.

Authors:  Hsin-Sheng Yang; Myung-Haing Cho; Halina Zakowicz; Glenn Hegamyer; Nahum Sonenberg; Nancy H Colburn
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

6.  Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma.

Authors:  Charles O Brown; Jeanine Schibler; Matthew P Fitzgerald; Neeraj Singh; Kelley Salem; Fenghuang Zhan; Apollina Goel
Journal:  Leuk Res       Date:  2013-03-26       Impact factor: 3.156

7.  Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.

Authors:  Yulia N Demchenko; Oleg K Glebov; Adriana Zingone; Jonathan J Keats; P Leif Bergsagel; W Michael Kuehl
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

8.  Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.

Authors:  Kelley Salem; Charles O Brown; Jeanine Schibler; Apollina Goel
Journal:  Exp Hematol       Date:  2012-10-11       Impact factor: 3.084

9.  The role of glucocorticoid receptor phosphorylation in Mcl-1 and NOXA gene expression.

Authors:  James T Lynch; Ramkumar Rajendran; Georgia Xenaki; Ilhem Berrou; Constantinos Demonacos; Marija Krstic-Demonacos
Journal:  Mol Cancer       Date:  2010-02-15       Impact factor: 27.401

Review 10.  Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.

Authors:  Johann Micallef; Moyez Dharsee; Jian Chen; Suzanne Ackloo; Ken Evans; Luqui Qiu; Hong Chang
Journal:  J Hematol Oncol       Date:  2010-04-07       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.